Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to …
P Ruggenenti, A Perna, C Zoccali… - Journal of the …, 2000 - journals.lww.com
Abstract In the Ramipril Efficacy in Nephropathy study, ramipril decreased the rate of GFR
decline (ΔGFR) and progression to end-stage renal disease (ESRD) in 352 patients with
proteinuric chronic nephropathies. This study investigated whether in these patients disease
outcome and response to treatment were affected by gender or insertion/deletion (I/D)
polymorphism of the angiotensin-converting enzyme (ACE) gene. ΔGFR (0.43±0.05 versus
0.48±0.08 ml/min per 1.73 m 2) and incidence of ESRD (23 and 22%, respectively) were …
decline (ΔGFR) and progression to end-stage renal disease (ESRD) in 352 patients with
proteinuric chronic nephropathies. This study investigated whether in these patients disease
outcome and response to treatment were affected by gender or insertion/deletion (I/D)
polymorphism of the angiotensin-converting enzyme (ACE) gene. ΔGFR (0.43±0.05 versus
0.48±0.08 ml/min per 1.73 m 2) and incidence of ESRD (23 and 22%, respectively) were …